<DOC>
	<DOCNO>NCT00562939</DOCNO>
	<brief_summary>The purpose study determine whether TLR-9 adjuvanted pneumococcal immunogenic pneumococcal vaccination alone HIV-infected adult .</brief_summary>
	<brief_title>Immune Response Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination HIV Infected Adults</brief_title>
	<detailed_description>Pneumococcal disease major source morbidity mortality HIV-patients . HIV-patients vaccine hyporesponders . A good immune response pneumococcal vaccination enhances vaccine effectiveness , thereby prevent morbidity mortality cause pneumococcal disease . Even optimized regimen contain conjugate polysaccharide pneumococcal vaccine use , 13 % immunized HIV patient high responder week 96 . Recent data indicate TLR9-agonists excellent vaccine adjuvant potential safe use immunocompetent well immunocompromised individual . The aim study evaluate qualitative quantitive immune response pneumococcal vaccination without TLR9-agonist HIV-infected adult</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Written inform consent authority statement provide accord local regulatory ethical practice use participant information sheet informed consent form approve responsible Ethics Committee . HIVseropositive individual . Pregnancy determine positive urine betahCG ( female ) Participant unwilling use reliable contraception method duration trial . Reliable method birth control include : pharmacologic contraceptive include oral , parenteral , transcutaneous delivery ; condom spermicide ; diaphragm spermicide ; surgical sterilization ; vaginal ring ; intrauterine device ; abstinence ; postmenopause ( female ) Currently breastfeed ( female ) Latest CD4 count &lt; 200 x106 cells/ÂµL Viral load ( HIV RNA ) &gt; 50 copies/mL HAART ( define least three antiretrovirals include either protease inhibitor NNRTI , i.e . combivir 300/150 mg x2 + stocrin 600 mg x1 minimum 6 month ) Previous enrollment study Any medical , psychiatric , social , occupational condition responsibility , judgment Principal Investigator ( PI ) , would interfere evaluation study objective ( severe alcohol abuse , severe drug abuse , dementia ) Unable follow protocol regimen Pneumococcal vaccination 5 year less prior inclusion Planned participation vaccination trial time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Antibody Formation</keyword>
	<keyword>Antibody Affinity</keyword>
	<keyword>Immunity</keyword>
	<keyword>Pneumococcal Vaccines</keyword>
	<keyword>Oligodeoxyribonucleotides</keyword>
</DOC>